Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

BMC Cancer

Huiyan Ma⁹  Yani Lu⁹  Kathleen E Malone⁵  Polly A Marchbanks⁴  Dennis M Deapen⁶  Robert Spirtas⁸  Ronald T Burkman³  Brian L Strom⁷  Jill A McDonald⁴  Suzanne G Folger⁴  Michael S Simon²  Jane Sullivan-Halley⁹  Michael F Press¹  Leslie Bernstein⁹ 

[1] Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA

[2] Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, 48201, USA

[3] Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, MA, 01199, USA

[4] Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA

[5] Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA

[6] Department of Preventive Medicine, University of Southern California, Los Angeles, CA, 90033, USA

[7] Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA

[8] Formerly Contraceptive and Reproductive Health Branch, Center for Population Research, National Institute of Child Health and Development, Bethesda, MD, 20892, USA

[9] Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA

关键词: p53;    HER2;    PR;    ER;    Luminal A;    Triple negative;    Racial disparity;    Mortality;    Breast cancer;   

Others  :  1079766
DOI  :  10.1186/1471-2407-13-225

 received in 2012-10-22, accepted in 2013-05-01,  发布年份 2013

【 摘 要 】

Background

Black women are more likely than white women to have an aggressive subtype of breast cancer that is associated with higher mortality and this may contribute to the observed black-white difference in mortality. However, few studies have investigated the black-white disparity in mortality risk stratified by breast cancer subtype, defined by estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Furthermore, it is not known whether additional consideration of p53 protein status influences black-white differences in mortality risk observed when considering subtypes defined by ER, PR and HER2 status.

Methods

Four biomarkers were assessed by immunohistochemistry in paraffin-embedded breast tumor tissue from 1,204 (523 black, 681 white) women with invasive breast cancer, aged 35–64 years at diagnosis, who accrued a median of 10 years’ follow-up. Multivariable Cox proportional hazards regression models were fit to assess subtype-specific black-white differences in mortality risk.

Results

No black-white differences in mortality risk were observed for women with triple negative (ER-negative [ER-], PR-, and HER2-) subtype. However, older (50–64 years) black women had greater overall mortality risk than older white women if they had been diagnosed with luminal A (ER-positive [ER+] or PR+ plus HER2-) breast cancer (all-cause hazard ratio, HR, 1.88; 95% confidence interval, CI, 1.18 to 2.99; breast cancer-specific HR, 1.51; 95% CI, 0.83 to 2.74). This black-white difference among older women was further confined to those with luminal A/p53- tumors (all-cause HR, 2.22; 95% CI, 1.30 to 3.79; breast cancer-specific HR, 1.89; 95% CI, 0.93 to 3.86). Tests for homogeneity of race-specific HRs comparing luminal A to triple negative subtype and luminal A/p53- to luminal A/p53+ subtype did not achieve statistical significance, although statistical power was limited.

Conclusions

Our findings suggest that the subtype-specific black-white difference in mortality risk occurs mainly among older women diagnosed with luminal A/p53- breast cancer, which is most likely treatable. These results further suggest that factors other than subtype may be relatively more important in explaining the increased mortality risk seen in older black women.

【 授权许可】

   
2013 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jatoi I, Anderson WF, Rao SR, Devesa SS: Breast cancer trends among black and white women in the United States. J Clin Oncol 2005, 23(31):7836-7841.
• [2]U.S. Mortality Files NCfHS, CDC: Female breast cancer death rates by race and ethnicity, U.S., 1999–2009. 2012. http://www.cdc.gov/cancer/breast/statistics/race.htm webcite
• [3]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S: Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
• [4]Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113(2):357-370.
• [5]O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16(24):6100-6110.
• [6]Sachdev JC, Ahmed S, Mirza MM, Farooq A, Kronish L, Jahanzeb M: Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl) 2010, 4:23-33.
• [7]Dookeran KA, Dignam JJ, Holloway N, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol 2012, 19(7):2334-2344.
• [8]Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109(9):1721-1728.
• [9]Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334.
• [10]Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1):4429-4434.
• [11]Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G: Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(2):479-485.
• [12]Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE: Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010, 70(2):575-587.
• [13]Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1–2):4-13.
• [14]Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008, 113(7):1521-1526.
• [15]Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011, 103(3):250-263.
• [16]Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443.
• [17]Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009, 9(Suppl 2):S73-S81.
• [18]Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65. BioMed Central Full Text
• [19]Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl 1):61-70.
• [20]Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14(24):8010-8018.
• [21]Hudis CA, Gianni L: Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl 1):1-11.
• [22]Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139.
• [23]Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11(3):R31. BioMed Central Full Text
• [24]Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009, 20:1071-1082.
• [25]Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, VanTuinen P, Ledbetter DH, Barker DF, Nakamura Y: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244(4901):217-221.
• [26]Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Genes Dev 1990, 4(1):1-8.
• [27]Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993, 85(15):1206-1219.
• [28]Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991, 88(11):5006-5010.
• [29]Allred DC, Elledge R, Clark GM, Fuqua SA: The p53 tumor-suppressor gene in human breast cancer. Cancer Treat Res 1994, 71:63-77.
• [30]Smith HS: Tumor-suppressor genes in breast cancer progression. Cancer Treat Res 1994, 71:79-96.
• [31]Pirollo KF, Bouker KB, Chang EH: Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000, 11(6):419-432.
• [32]Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999, 80(12):1968-1973.
• [33]Hill KA, Sommer SS: p53 as a mutagen test in breast cancer. Environ Mol Mutagen 2002, 39(2–3):216-227.
• [34]Rossner P Jr, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 2009, 13(9B):3847-3857.
• [35]Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32.
• [36]Lukas J, Niu N, Press MF: p53 mutations and expression in breast carcinoma in situ. Am J Pathol 2000, 156(1):183-191.
• [37]Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, el-Naggar A, Press MF: p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999, 18(1):29-41.
• [38]Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL, Marchbanks PA, Spirtas R, Burkman RT, Deapen D: Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 2011, 29(25):3358-3365.
• [39]Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK: The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 2002, 12(4):213-221.
• [40]Press MF, Greene GL: An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest 1984, 50(4):480-486.
• [41]Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP: Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 2002, 67(9):799-813.
• [42]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134(7):e48-e72.
• [43]Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou J-Y, Wardeh R, Li Y-T, Guzman R, Ma Y: Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(18):6598-6607.
• [44]Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L: Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens. J Clin Oncol 2002, 20(14):3095-3105.
• [45]Saffari B, Bernstein L, Hong DC, Sullivan-Halley J, Runnebaum IB, Grill HJ, Jones LA, El-Naggar A, Press MF: Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005, 15(5):952-963.
• [46]Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A: p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 2000, 77(2):237-242.
• [47]Cox D, Oakes D: Analysis of survival data. London, England: Chapman & Hall; 1984.
• [48]Rothman KJ, Greenland S: Modern epidemiology. Philadelphia: Lippincott-Raven; 1998.
• [49]Allison P: Survival Analysis Using SAS®: A Practical Guide Second Edition. 2nd edition. Cary, NC: SAS Institute Inc.; 2010.
• [50]Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003, 163(1):49-56.
• [51]Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr: Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 2012, 104(5):406-414.
• [52]Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005, 294(14):1765-1772.
• [53]Bassett MT, Krieger N: Social class and black-white differences in breast cancer survival. Am J Public Health 1986, 76(12):1400-1403.
• [54]Gorin SS, Heck JE, Cheng B, Smith SJ: Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 2006, 166(20):2244-2252.
• [55]Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 2002, 94(7):490-496.
• [56]Jatoi I, Becher H, Leake CR: Widening disparity in survival between white and African-American patients with breast carcinoma treated in the US. Department of Defense Healthcare system. Cancer 2003, 98(5):894-899.
• [57]Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW: Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 2003, 81(1):21-31.
• [58]Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 2005, 23(27):6639-6646.
• [59]Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, Malone KE, Strom BL, Ursin G, Marchbanks PA: Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 2009, 18(8):2214-2220.